These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Barsoum IB; Smallwood CA; Siemens DR; Graham CH Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068 [TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. Villasboas JC; Ansell S Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012 [TBL] [Abstract][Full Text] [Related]
11. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Kerr KM; Nicolson MC Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720 [TBL] [Abstract][Full Text] [Related]
12. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer]. Hamanishi J; Konishi I Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890 [TBL] [Abstract][Full Text] [Related]
13. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735 [TBL] [Abstract][Full Text] [Related]
14. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Swaika A; Hammond WA; Joseph RW Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122 [TBL] [Abstract][Full Text] [Related]
15. [Research update on PD-1/PD-L1 pathway in hematological diseases]. Li Y; Wang J; Ke XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1523-7. PubMed ID: 22169317 [TBL] [Abstract][Full Text] [Related]
16. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. Guan J; Lim KS; Mekhail T; Chang CC Arch Pathol Lab Med; 2017 Jun; 141(6):851-861. PubMed ID: 28418281 [TBL] [Abstract][Full Text] [Related]
18. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis. Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977 [TBL] [Abstract][Full Text] [Related]
19. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. He J; Hu Y; Hu M; Li B Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 inhibition with MPDL3280A for solid tumors. Cha E; Wallin J; Kowanetz M Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]